Advances in the application of recombinase-aided amplification combined with CRISPR-Cas technology in quick detection of pathogenic microbes

Front Bioeng Biotechnol. 2023 Aug 31:11:1215466. doi: 10.3389/fbioe.2023.1215466. eCollection 2023.

Abstract

The rapid diagnosis of pathogenic infections plays a vital role in disease prevention, control, and public health safety. Recombinase-aided amplification (RAA) is an innovative isothermal nucleic acid amplification technology capable of fast DNA or RNA amplification at low temperatures. RAA offers advantages such as simplicity, speed, precision, energy efficiency, and convenient operation. This technology relies on four essential components: recombinase, single-stranded DNA-binding protein (SSB), DNA polymerase, and deoxyribonucleoside triphosphates, which collectively replace the laborious thermal cycling process of traditional polymerase chain reaction (PCR). In recent years, the CRISPR-Cas (clustered regularly interspaced short palindromic repeats-associated proteins) system, a groundbreaking genome engineering tool, has garnered widespread attention across biotechnology, agriculture, and medicine. Increasingly, researchers have integrated the recombinase polymerase amplification system (or RAA system) with CRISPR technology, enabling more convenient and intuitive determination of detection results. This integration has significantly expanded the application of RAA in pathogen detection. The step-by-step operation of these two systems has been successfully employed for molecular diagnosis of pathogenic microbes, while the single-tube one-step method holds promise for efficient pathogen detection. This paper provides a comprehensive review of RAA combined with CRISPR-Cas and its applications in pathogen detection, aiming to serve as a valuable reference for further research in related fields.

Keywords: clustered regularly interspaced short palindromic repeats associated proteins; pathogenic microbes; quick detection; recombinase-aided amplification; specific diagnosis.

Publication types

  • Review

Grants and funding

This study was financially supported by the Science and Technology Development Fund, Macau SAR (Grant 0024/2022/A), the Science and Technology Planning Project of Guangdong Province (2020B1212030008), study on the role and molecular mechanism of HuD abnormal expression in the development and progression of non-small cell lung cancer (Y202147513), and 2022 National Student Innovation and Entrepreneurship Training Program Project (Item Number: 202211842047). Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang province (KFJJ2023005). These funders did not participate in the designing, performing or reporting in the current study.